Unlocking the language of the heart
Harnessing the power of the electrical signal of the heart to transform cardiac care through cutting-edge AI solutions
Anumana™ is an AI-driven health technology company from nference, building and commercializing AI solutions to improve patient care throughout the cardiac care continuum.
Our Impact
The Impact of AI Algorithms in Cardiology
Listen to Dr. Paul Friedman, a Professor of Medicine and Chair of the Department of Cardiovascular Medicine at Mayo Clinic and Anumana advisor, discuss the potential of AI algorithms in advancing early diagnosis and intervention in cardiology.
Diagnostic Electrocardiography
Serious cardiovascular diseases affect millions of people worldwide, often going undiagnosed until symptoms advance and patients deteriorate, at times resulting in life-threatening events and creating a multi-billion dollar healthcare burden. Anumana’s AI solutions enable earlier diagnosis of these otherwise hidden diseases, empowering clinicians to intervene with treatments earlier and improve outcomes.
Electrophysiology
Today, the power of AI is just beginning to be leveraged in clinical decision support and has the potential to provide immense value during interventional procedures. Anumana’s algorithms and software have the potential to improve procedure accuracy, reduce procedure times, improve medication management, and improve patient safety and outcomes.
Our Difference
Rich, Proprietary Data Fueled R&D
Anumana leverages the largest combined dataset of electrophysiological data, longitudinal patient history, and outcomes in the world. This dataset was developed from multi-year, exclusive data partnerships with leading academic medical centers from Anumana’s parent company, nference. This real-world evidence generation platform, nSights, is inclusive of 11M patients spanning 20+ years and transforms unstructured data (i.e. clinical notes, echocardiogram reports) and semi-structured (i.e. lab tests, medications, appointments, etc) data into labeled data format at scale. This extensive "deep data" platform fuels Anumana's research and development.
Cutting-Edge AI Medical Device Solutions
Anumana transforms research-grade algorithms into medical devices, conducting necessary clinical validation for regulatory clearance, and working with leading clinical experts around the world. Anumana's portfolio includes dozens of first-in-class algorithms, including ECG-AI algorithms for early disease detection and EGM-AI algorithms to improve EP procedures.
Innovative Clinical Software & Integration
Anumana builds and commercializes clinician-facing software and solutions for seamless integration of its technology into existing clinical workflows. Anumana's software solutions integrate with EMRs and other point-of-care technology used within the clinician's existing workflow.
Diagnostic Electrocardiography Pipeline
Anumana has a robust FDA-ready pipeline of ECG-AI algorithms, with 75+ peer-reviewed publications that showcase the potential of these algorithms for early cardiovascular disease detection and improved prognosis.
Low Ejection Fraction
FDA Breakthrough Device Designation; FDA Cleared
Phase: Market Authorization
Pulmonary Hypertension
Granted FDA Breakthrough Device Designation
Phase: Validation
Cardiac Amyloidosis
Granted FDA Breakthrough Device Designation
Phase: Validation
Hyperkalemia
Granted FDA Breakthrough Device Designation
Phase: Pre-Submission
Atrial Fibrillation in Normal Sinus Rhythm
Phase: Pre-Submission
Hypertrophic Cardiomyopathy (HCM)
Phase: Development
Myocarditis
Phase: Development
Aortic Stenosis
Phase: Development
Early Stage Development Programs
Phase: Development
Electrophysiology Pipeline
Anumana has a highly fertile portfolio of EP applications under development, aiming to increase procedure accuracy, reduce procedure time, and improve patient safety and outcomes.
Electro-anatomical Mapping
FDA Cleared
Phase: Market Authorization
Pulmonary Vein Potential Identification
Phase: Development
Ventricular Tachycardia Identification
Phase: Development
Supraventricular Tachycardia Identification
Phase: Development
Early Stage Development Programs
Phase: Development
News and Press Releases
See Anumana’s work in the news
Anumana Appoints Maulik Nanavaty as CEO
Oct. 19th, 2023
Anumana Receives U.S. FDA 510(k) Clearance for ECG-AI Algorithm to Detect Low Ejection Fraction
Based on pioneering research from Mayo Clinic, ECG-AI LEF aims to aid physicians in identifying low ejection fraction in patients at risk of heart failure
Oct. 2nd, 2023
Anumana Receives U.S. FDA Breakthrough Device Designation for its Cardiac Amyloidosis Algorithm
Developed in collaboration with Mayo Clinic, with support from Pfizer, this ECG-AI algorithm aims to aid physicians in earlier identification of cardiac amyloidosis
Jun. 21st, 2023
Anumana Named to Fierce Medtech’s 2022 Fierce 15
AI-driven startup from nference and Mayo Clinic Platform positioned to transform cardiac care
Mar. 20th, 2023
Our Science & Publications
Learn more about Anumana’s algorithms validated in 75+ peer reviewed publications.
Digitizing paper based ECG files to foster deep learning based analysis of existing clinical datasets: An exploratory analysis
Aug. 8th, 2022
Community-based participatory research application of an artificial intelligence-enhanced electrocardiogram for cardiovascular disease screening: A FAITH! Trial ancillary study
Nov. 13th, 2022
Prospective evaluation of smartwatch-enabled detection of left ventricular dysfunction
Nov. 14th, 2022
Clinician Adoption of an Artificial Intelligence Algorithm to Detect Left Ventricular Systolic Dysfunction in Primary Care.
Nov. 1st, 2022
In the Media
At Mayo Clinic, AI engineers face an ‘acid test’: Will their algorithms help...
In just the past three years, the team has published more than two dozen studies on AI in cardiology, and it is now field-testing an algorithm to detect a weak heart pump in dozens of primary care clinics.
Stat
Dec. 18th, 2019
Download Our One-Pager
Featuring key corporate highlights and an overview of Anumana's technology
@2023 anumana, Inc. All rights reserved.